Red cell alloimmunization in a diverse population of transfused patients with thalassaemia

Thompson, A. A.; Cunningham, M. J.; Singer, S. T.; Neufeld, E. J.; Vichinsky, E.; Yamashita, R.; Giardina, P.; Kim, H. Y.; Trachtenberg, F.; Kwiatkowski, J. L.

Br J Haematol. 2011 Feb 18; 153(1):121-8


Red blood cell (RBC) transfusion is the primary treatment for severe forms of thalassaemia. Pre-storage screening has resulted in decreased transfusion-transmitted infections, but anti-RBC antibodies remain a major problem. We report on 697 participants who had ever received transfusions. Allo- and autoantibody rates were compared with respect to splenectomy status, ethnicity, diagnosis, duration of transfusions, treatment centre, and age at transfusion initiation, together with rates before and after 1990, when leucoreduction methods were routine at thalassaemia treatment centres. Allo- and autoantibodies were reported in 115 (16.5%) and 34 (4.9%) subjects, respectively. Splenectomized patients were more likely to have alloantibodies [odds ratio (OR) = 2.528, P

Read More on PubMed